Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | LIPE | Q05469 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2928370 | 1.00 | SMN1; SMN2 (0.52) | SMN1; SMN2LMNAHRH3MEN1KMT2A | |
| SCHEMBL2925937 | 0.89 | HRH3 (0.48) | SMN1; SMN2LMNAHRH3ACACB | |
| SCHEMBL2925933 | 0.89 | HRH3 (0.48) | SMN1; SMN2LMNAHRH3ACACB | |
| SCHEMBL2924536 | 0.82 | HRH3 (0.57) | HRH3SCN9ALIPE | |
| SCHEMBL2924533 | 0.82 | HRH3 (0.57) | HRH3SCN9ALIPE | |
| SCHEMBL18422974 | 0.78 | CYP2C9 (0.51) | SMN1; SMN2LMNAMEN1KMT2AGAA | |
| SCHEMBL16771257 | 0.76 | GPR119 (0.52) | SMN1; SMN2MEN1KMT2AGAAMAPT | |
| SCHEMBL2925951 | 0.75 | HRH3 (0.62) | LMNAHRH3KMT2AMAPTLIPE | |
| SCHEMBL31695270 | 0.75 | PIK3CD (0.55) | MEN1KMT2A | |
| SCHEMBL2925949 | 0.75 | HRH3 (0.62) | LMNAHRH3KMT2AMAPTLIPE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2167498-B1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2010-09-15 | — | — | EP | claimed |
| EP-2158189-B1 | CYCLOHEXYL DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-09-15 | — | — | EP | claimed |
| EP-2158189-A1 | CYCLOHEXYL DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2010-03-03 | — | — | EP | claimed |
| US-7544683-B2 | Cyclohexyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-06-09 | — | — | US | claimed |
| US-20090005380-A1 | CYCLOHEXYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-01 | — | — | US | claimed |
| WO-2008151957-A1 | CYCLOHEXYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-12-18 | — | — | WO | claimed |
| EP-2158189-B1 | CYCLOHEXYL DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-09-15 | — | — | EP | disclosed |
| US-7544683-B2 | Cyclohexyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-20090005380-A1 | CYCLOHEXYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005380-A1 | CYCLOHEXYL DERIVATIVES | HRH3, HRH4, HCAR2 | SMN1; SMN2 3660/4885LMNA 2554/4885HRH3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.